Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 7Lung Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Solid Tumors 1Adenoma, Islet Cell 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × PM 01183 × Clear all
NCT01525589 2020-09-25

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

PharmaMar

Phase 2 Completed
111 enrolled 31 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡